Douglas Joshua

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 849 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3

Meletios Α. Dimopoulos, Robert A. Kyle, Jean-Paul Fermand et al. · Blood · 2011 · 450 citations

Medicine, Hematology, Oncology +14

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation

Brian G.M. Durie, Robert A. Kyle, Andrew R. Belch et al. · The Hematology Journal · 2003 · 425 citations

Medicine, Hematology, Internal Medicine +16

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Hartmut Goldschmidt, Rubén Niesvizky et al. · The Lancet Oncology · 2017 · 401 citations

Medicine, Oncology, Pharmacology +14